Seeking Alpha

InSite Vision, Inc. (INSV)

  • Aug. 13, 2014, 4:22 PM
    • InSite Vision (OTCQB:INSV) Q2 results: Revenues: $6.3M (-67.0%); Operating Expenses: $4.1M (-22.3%); Operating Income: $2.3M (-83.9%); Net Income: $37.1M (+206.6%); EPS: $0.28 (+211.1%); Quick Assets: $2.5M (-70.0%).
    • No financial guidance given.
    | Aug. 13, 2014, 4:22 PM | Comment!
INSV vs. ETF Alternatives
Company Description
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's... More